Observational Follow-up Study of Haplo-identical Transplants in Fanconi Disease — HAPLO-FANCONI  

Fanconi Syndrome Clinical Trial

Official title: Etude Observationnelle de Suivi Des Greffes Haplo-identique Dans la Maladie de Fanconi

Status Not yet recruiting

Clinical Trial Summary

This observational protocol will allow for an independent, prospective evaluation of the improvement in survival of patients with Fanconi disease in hematological deadlock due to the absence of an HLA-identical donor and having received a haploidentical transplant.

Clinical Trial Description

Fanconi's disease is characterised by a constitutional defect in DNA repair which results in the occurrence of bone marrow failure and haematological malignancies, mainly myeloid: at the age of 40, the cumulative incidence of these two types of pathology reaches almost 100%. The only curative treatment for haemtalogocial diseases is allogenic hematopoietic stem cell transplant. Transplantation modalities must be adapted to the particular susceptibility of these patients to DNA bridging agents and radiotherapy. HSC transplantation is indicated with an unaffected matched related or matched unrelated donor when the patient has severe bone marrow failure or a poor prognostic clonal evolution (cytogenetic evolution or proven haemopathy). Alternative transplants (9/10 pheno-identical, haplo-identical and placental blood donors) were no longer proposed in most cases due to the frequency of severe complications (graft-versus-host disease, viral infections) and the catastrophic medium-term survival of around 40% (Dufort, Bone Marrow Transplant 2012, Gluckman Biol Blood Marrow Transplant. 2007). The development over the last decade of new haploidentical or phenoidentical 9/10 transplant protocols with unmodified grafts and GVH prophylaxis with post-transplant cyclosphosphamide or ex vivo T-depletion adapted to the particular susceptibility of patients with Fanconi disease has reduced the incidence of these severe complications.

This observational protocol will allow for an independent, prospective evaluation of the improvement in survival of patients with Fanconi disease in hematological deadlock due to the absence of an HLA-identical donor and having received a haploidentical transplant ;

Related Conditions & MeSH terms

• Fanconi Anemia
• Fanconi Syndrome

• NCT number: NCT05903365
• Study type: Observational
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Flore Sicre de Fontbrune, Dr
• Phone: +33 1 42 49 42 67
• Email: flore.sicre-de-fontbrune@aphp.fr
• Status: Not yet recruiting
• Start date: June 2023
• Completion date: March 2028